AI Article Synopsis
- A Japanese patient with HIV-related Kaposi sarcoma presented with multiple skin lesions and significant swelling in both groin areas.
- The patient underwent extensive treatment with pegylated liposomal doxorubicin (PLD) over 10 years, exceeding the standard lifetime dosage without experiencing serious side effects.
- Ultimately, the patient passed away from pancreatic cancer rather than complications from the KS or the treatments received.
Article Abstract
We report a Japanese patient with HIV-associated Kaposi sarcoma (KS) who had many cutaneous KS lesions with extensive bilateral groin edema. As the KS was refractory to antiretroviral therapy and pegylated liposomal doxorubicin (PLD), he was administered PLD up to a cumulative dose of 940 mg/m in 10 years, which exceeded the recommended lifetime dose (550 mg/m). However, the patient showed no major adverse events, including cardiotoxicity, and he eventually died of pancreatic cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jiac.2019.08.016 | DOI Listing |
Publication Analysis
Top Keywords
pegylated liposomal
8
liposomal doxorubicin
8
recommended lifetime
8
lifetime dose
8
japanese patient
8
patient hiv-associated
8
hiv-associated kaposi
8
kaposi sarcoma
8
long-term administration
4
administration pegylated
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!